Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials
This review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/8/5/322 |
| _version_ | 1797536733697409024 |
|---|---|
| author | Bibhuti B. Das William B. Moskowitz Javed Butler |
| author_facet | Bibhuti B. Das William B. Moskowitz Javed Butler |
| author_sort | Bibhuti B. Das |
| collection | DOAJ |
| description | This review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion rather than on evidence from controlled clinical trials. It is difficult to conclude whether the drugs that are well established in adult HF trials are also beneficial for children because of tremendous heterogeneity in the mechanism of HF in children and variations in the pharmacokinetics and pharmacodynamics of drugs from birth to adolescence. The lessons learned from adult trials can guide pediatric cardiologists to design clinical trials of the newer drugs that are in the pipeline to study their efficacy and safety in children with HF. This paper<i>’</i>s focus is that the reader should specifically think through the pathophysiological mechanism of HF and the mode of action of drugs for the selection of appropriate pharmacotherapy. We review the drug and device trials in adults with HF to highlight the knowledge gap that exists in the pediatric HF population. |
| first_indexed | 2024-03-10T12:05:00Z |
| format | Article |
| id | doaj.art-b0b68bc7b5f94ff298185a5f04dbee7f |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-10T12:05:00Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-b0b68bc7b5f94ff298185a5f04dbee7f2023-11-21T16:39:19ZengMDPI AGChildren2227-90672021-04-018532210.3390/children8050322Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult TrialsBibhuti B. Das0William B. Moskowitz1Javed Butler2Heart Center, Department of Pediatrics, Mississippi Children’s Hospital, University of Mississippi Medical Center, Jackson, MS 39212, USAHeart Center, Department of Pediatrics, Mississippi Children’s Hospital, University of Mississippi Medical Center, Jackson, MS 39212, USADepartment of Medicine, University of Mississippi Medical Center, Jackson, MS 39212, USAThis review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion rather than on evidence from controlled clinical trials. It is difficult to conclude whether the drugs that are well established in adult HF trials are also beneficial for children because of tremendous heterogeneity in the mechanism of HF in children and variations in the pharmacokinetics and pharmacodynamics of drugs from birth to adolescence. The lessons learned from adult trials can guide pediatric cardiologists to design clinical trials of the newer drugs that are in the pipeline to study their efficacy and safety in children with HF. This paper<i>’</i>s focus is that the reader should specifically think through the pathophysiological mechanism of HF and the mode of action of drugs for the selection of appropriate pharmacotherapy. We review the drug and device trials in adults with HF to highlight the knowledge gap that exists in the pediatric HF population.https://www.mdpi.com/2227-9067/8/5/322acute heart failure syndromepediatric heart failurepharmacotherapy for heart failuredevice therapy for chronic heart failure |
| spellingShingle | Bibhuti B. Das William B. Moskowitz Javed Butler Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials Children acute heart failure syndrome pediatric heart failure pharmacotherapy for heart failure device therapy for chronic heart failure |
| title | Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials |
| title_full | Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials |
| title_fullStr | Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials |
| title_full_unstemmed | Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials |
| title_short | Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials |
| title_sort | current and future drug and device therapies for pediatric heart failure patients potential lessons from adult trials |
| topic | acute heart failure syndrome pediatric heart failure pharmacotherapy for heart failure device therapy for chronic heart failure |
| url | https://www.mdpi.com/2227-9067/8/5/322 |
| work_keys_str_mv | AT bibhutibdas currentandfuturedruganddevicetherapiesforpediatricheartfailurepatientspotentiallessonsfromadulttrials AT williambmoskowitz currentandfuturedruganddevicetherapiesforpediatricheartfailurepatientspotentiallessonsfromadulttrials AT javedbutler currentandfuturedruganddevicetherapiesforpediatricheartfailurepatientspotentiallessonsfromadulttrials |